Ibex Investors’s Theravance Biopharma TBPH Stock Holding History

Ibex Investors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-45,225	Closed	-$739	–	102
2019 Q2	$739	Buy	45,225 +13,102	+41%	+$265K	0.06%	43
2019 Q1	$728K	Sell	32,123 -3,681	-10%	-$93.3K	0.06%	47
2018 Q4	$916K	Sell	35,804 -10,297	-22%	-$278K	0.15%	29
2018 Q3	$1.51M	Buy	+46,101	New	+$1.26M	0.84%	23

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ibex Investors's TBPH Position: Q3 2019 in Review

Ibex Investors sold out of Theravance Biopharma (TBPH) in Q3 2019, closing a stake of 45,225 shares — an estimated $739 sold.

Ibex Investors first reported a position in TBPH in Q3 2018 and held it in 4 quarters. The position peaked at $1.51M in Q3 2018. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

Ibex Investors reported no remaining Theravance Biopharma position as of Q3 2019 after selling out during the quarter.
Ibex Investors sold 45,225 Theravance Biopharma shares in Q3 2019, an estimated $739.
Ibex Investors first reported a position in Theravance Biopharma in Q3 2018 and held it in 4 quarters.
Ibex Investors's Theravance Biopharma position peaked at $1.51M in Q3 2018.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Ibex Investors's 13F filing for Q3 2019, filed 1 Nov 2019.